RNA

Avidity Biosciences, Inc.

20.10 USD
-0.01 (-0.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Avidity Biosciences, Inc. stock is up 72.83% since 30 days ago. The next earnings date is May 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
26 Feb 14:53 15 Mar, 2024 15.00 PUT 173 108
29 Feb 14:40 15 Mar, 2024 25.00 CALL 491 33
29 Feb 15:26 21 Jun, 2024 12.50 CALL 100 272
29 Feb 16:28 15 Mar, 2024 17.50 CALL 100 225
29 Feb 16:29 15 Mar, 2024 20.00 CALL 166 5173
01 Mar 20:17 21 Jun, 2024 17.50 PUT 100 100
01 Mar 20:31 15 Mar, 2024 22.50 PUT 100 0
01 Mar 20:59 15 Mar, 2024 30.00 CALL 1972 0
01 Mar 20:59 15 Mar, 2024 25.00 CALL 600 514
01 Mar 20:59 15 Mar, 2024 25.00 CALL 358 514

About Avidity Biosciences, Inc.

Avidity Biosciences, Inc. engages in the development of oligonucleotide-based therapies. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the. treatment of Duchenne Muscular Dystrophy.

  • Needham
    Thu Feb 29, 08:49
    buy
    confirm
  • Chardan Capital
    Thu Feb 29, 08:07
    buy
    confirm